RxDoctor Payments Data

Daniel Taylor, PA

Medical · Denver, CONPI 1629549407

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $47,925 of the $67,037 with a category attached, or 71.5%. 13 manufacturers reported payments, led by Viiv Healthcare Company at 58.0% of the total. Among medical clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$67,037in general payments, 2019–2025

Across 334 payments — averaging $200.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$39K
  • Gilead$27K
  • Merck$569
  • GSK$146
  • Janssen Scientific Affairs, LLC$127
  • Janssen Products, LP$122
  • plus $281 from 7 others

What the payments were for

  • Speaking & faculty fees$47,92571%
  • Travel & lodging$8,95313%
  • Food & beverage$10,15915%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$67,037 in reported general payments places this provider in the 95th percentile of 766 medical providers in Colorado.

See all medical providers in Colorado

Medicare billing

Part B allowed, 2024
$8,151
Medicare patients
23
Services billed
78

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala130$493,184
OdefseyEmtricitab/Rilpiviri/Tenof Ala45$157,830
DescovyEmtricitabine/Tenofov Alafenam54$116,842
TivicayDolutegravir Sodium35$100,557
JulucaDolutegravir/Rilpivirine18$61,190
DovatoDolutegravir Sodium/Lamivudine17$49,650
TriumeqAbacavir/Dolutegravir/Lamivudi11$40,399
PifeltroDoravirine18$31,515
Ambien CrZolpidem Tartrate13$8,431
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)12$4,767
Sumatriptan15$2,599
Testosterone28$2,553
Albuterol Sulfate HfaAlbuterol Sulfate32$651
Fluconazole12$613
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine13$424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$26,913$610,026184 claims
Viiv Healthcare CompanyTivicay, Juluca, Dovato, Triumeq$38,879$251,79781 claims
MerckPifeltro$569$31,51518 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$22$8812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 766 medical providers in Colorado.

Other medical in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →